Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2019
Price : $35 *
At a glance
- Drugs CXD 101 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- 16 Apr 2019 Planned End Date changed from 1 Dec 2017 to 1 Nov 2019.
- 16 Apr 2019 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2019.
- 16 Apr 2019 Status changed from completed to recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History